Vitamin D deficiency in patients with intellectual disabilities: Prevalence, risk factors and management strategies

British Journal of Psychiatry

Volumn 205, Issue 6, 2014, Pages 458-464

  Frighi, Valeria ^a   Morovat, Alireza ^b   Stephenson, Matthew T ^c   White, Sarah J ^d   Hammond, Christina V ^d   Goodwin, Guy M ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTICONVULSIVE AGENT; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; BONE DENSITY CONSERVATION AGENT; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FEMALE; FRAGILITY FRACTURE; HIGH RISK POPULATION; HUMAN; INTELLECTUAL IMPAIRMENT; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MENTAL PATIENT; OBESITY; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; RISK FACTOR; SCREENING; SEASONAL VARIATION; SKIN COLOR; SUMMER; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WALKING DIFFICULTY; WINTER; BLOOD; COMPLICATION; DRUG ADMINISTRATION; FRACTURES, BONE; MIDDLE AGED; PATHOPHYSIOLOGY; SUNLIGHT; TREATMENT OUTCOME;

ADULT; BONE DENSITY CONSERVATION AGENTS; CHOLECALCIFEROL; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; INTELLECTUAL DISABILITY; MALE; MIDDLE AGED; MOBILITY LIMITATION; OBESITY; OSTEOPOROSIS; RISK FACTORS; SUNLIGHT; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84916638288     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.143511     Document Type: Article

References (42)

1. Holick M F. Vitamin D deficiency. New Engl J Med 2007; 357: 266-81.
2. Vanlint S, Nugent M, Durvasula S. Vitamin D and people with intellectual disability. Aust Fam Physician 2008; 37: 348-51.
3. Vanlint S, Nugent M. Vitamin D and fractures in people with intellectual disability. J Intellect Dis Res 2006; 50 : 761-7.
4. Zubillaga P, Garrido A, Mugica I, Ansa J, Zabalza R, Emparanza JI. Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome. Eur J Clin Nutr 2006; 60: 605-9.
5. Kilpinen-Loisa P, Arvio M, Ilvesmaä ki V, Maä kitie O. Vitamin D status and optimal supplementation in institutionalized adults with intellectual disability. J Intellect Disabil Res 2009; 53: 1014-23.
6. Wong TS, Lau VM, Lim W, Fung G. A survey of vitamin D level in people with learning disability in long-stay hospital wards in Hong Kong. J Intellect Disabil 2006; 10: 47-59.
7. Srikanth R, Cassidy G, Joiner C, Teeluckdharry S. Osteoporosis in people with intellectual disabilities: a review and a brief study of risk factors for osteoporosis in a community sample of people with intellectual disabilities. J Intellect Disabil Res 2011; 55 : 53-62
8. Schrager S, Kloss C, Ju, AW. Prevalence of fractures in women with intellectual disabilities: a chart review. J Intellect Disabil Res 2007; 5: 253-9.
9. Tannenbaum TN, Lipworth L, Baker S. Risk of fractures in an intermediate care facility for persons with mental retardation. Am J Ment Retard 1989; 93: 444-51.
10. Lohiya GS, Crinella FM, Tan-Figueroa L, Caires S, Lohiya S. Fracture epidemiology and control in a developmental center. West J Med 1999; 170: 203-9.
11. Glick NR, Fischer MH, Heisey DM, Leverson GE, Mann DC. Epidemiology of fractures in people with severe and profound developmental disabilities. Osteoporosis Int 2005; 16: 389-96
12. Jancar J, Jancar MP. Age-related fractures in people with intellectual disability and epilepsy. J Intellect Disabil Res 1998; 42: 429-33.
13. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. National Academy Press, 2010.
14. National Osteoporosis Society. Vitamin D and bone health: a practical clinical guideline for patient management. NOS, 2013 (www.nos.org.uk/document.doc?id=1352).
15. Frighi V, Stephenson MT, Morovat A, Jolley IE, Trivella M, Dudley CA, et al. Safety of antipsychotics in people with intellectual disability. Br J Psychiatry 2011; 199: 289-95.
16. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporosis Int 2007; 18: 129-42.
17. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373-8.
18. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85 : 860-8.
19. Bouillon R, Van Schoor NM, Gielen E, Boonen S, Matthieu C, Vanderschueren D, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013; 98: E1283-304.
20. Lawson DE, Paul AA, Black AE, Cole TJ, Mandal AR, Davie M. Relative contributions of diet and sunlight to vitamin D state in the elderly. Br Med J 1979; 2: 303-5.
21. Black LJ, Walton J, Flynn A, Kiely M. Adequacy of vitamin D intakes in children and teenagers from the base diet, fortified foods and supplements. Public Health Nutr 2014; 17: 721-31.
22. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8
23. Faurschou A, Beyer DM, Schmedes A, Bogh MK, Philipsen PA, Wulf HC. The relation between sunscreen layer thickness and vitamin D production after ultraviolet B exposure: a randomized clinical trial. Br J Dermatol 2012; 167: 391-5
24. Hawli Y, Nasrallah M, El-Hajj Fuleihan G. Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nat Rev Endocrinol 2009; 5: 327-34
25. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis Int 2009; 20: 239-44
26. National Institute for Health and Care Excellence. Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. NICE, 2008 (http://www.nice.org.uk/nicemedia/live/11748/42508/42508.pdf)
27. Chief Medical Officers of England, Wales, Northern Ireland and Scotland. Vitamin D - Advice On Supplements for at Risk Groups. Department of Health, Welsh Government, Department of Health, Social Services and Public Safety and the Scottish Government, 2012 (https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/213703/dh-132508.pdf).
28. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014; 383: 146-55.
29. Lawrence TM, White CT, Wenn R, Moran CG. The current hospital costs of treating hip fractures. Injury 2005; 36: 88-91.
30. British Orthopaedic Association. The Care of Patients with Fragility Fractures. The British Orthopaedic Association, 2007 (http://www.nhfd.co.uk/003/hipfracturer.nsf/luMenuDefinitions/FCEF9FCB98A1B8EB802579C900553996/$file/Blue-Book.pdf?OpenElement).
31. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A pooled analysis of Vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40-9.
32. Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H. Low serum vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J 2012; 14: 88-92.
33. Tiangga E, Gowda A, Dent JA. Vitamin D deficiency in psychiatric in-patients and treatment with daily supplements of calcium and ergocalciferol. Psychiatr Bull 2008; 32: 390-3.
34. Agorastos A, Weinas A, Agorastos AD, Wiedemann K. Psychosis-induced vitamin D deficiency with secondary hyperparathyroidism and osteoporotic fractures. Gen Hosp Psychiatry 2011; 33: 641.e3-5.
35. Gracious BL, Finucane TL, Friedman-Campbell M, Messing S, Parkhurst MN. Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. BMC Psychiatry 2012; 12 : 38.
36. Crews M, Lally J, Gardner-Sood P, Howes O, Bonaccorso S, Smith S, et al. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res 2013; 150: 533-7.
37. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012; 25: 415-29.
38. Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int 2012; 23: 2081-92.
39. Abukhadir SS, Mohamed N, Mohamed N. Pathogenesis of alcohol-induced osteoporosis and its treatment: a review. Curr Drug Targets 2013; 14: 1601-10.
40. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitarygonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008; 69: 385-91.
41. Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Res 2007; 93: 136-43.
42. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 138-51.